Leadership
Milestone Pharmaceuticals Grants 33,000 Options to One New Employee Under Nasdaq Rule
By News Desk ·
Key takeaways
- Milestone Pharmaceuticals granted 33,000 options to purchase common shares to one new employee.
- The options carry a grant date of November 2, 2026 and an exercise price of $0.72 per share.
- 25% of the option shares vest on the one-year anniversary, with the balance in 36 monthly installments.
- The award was made under Nasdaq Listing Rule 5635(c)(4) as an inducement to the employee's hiring.
Milestone Pharmaceuticals granted 33,000 options to purchase its common shares to one new employee, with an exercise price of $0.72 per share, the company said in a GlobeNewswire release. The award was made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to the hiring.
Milestone's 2021 Inducement Plan Award
The options were granted under Milestone Pharmaceuticals' 2021 Inducement Plan, which the Compensation Committee and the Board of Directors previously approved. The grant date is November 2, 2026, and the exercise price equals the closing price of Milestone's common shares on that date.
The shares subject to the options vest over four years. A quarter of the shares vest on the one-year anniversary of the vesting commencement date, and the balance vests in 36 successive equal monthly installments thereafter. Vesting is subject to the award holder's continuous service through each vesting date and to the terms of the plan and its standard grant agreements.
Milestone said the plan is used exclusively for equity awards to individuals who were not previously employees of the company, or who return after a bona fide period of non-employment, as an inducement to their entering employment. The release names Kevin Gardner for investor relations and Rebecca Novak for media relations.
Milestone's Commercial-Stage Profile
Milestone is a commercial-stage biopharmaceutical company whose lead product is CARDAMYST (etripamil) nasal spray, a calcium channel blocker that is FDA-approved for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, according to akta.pro company records. Etripamil is also in Phase 3 development for symptomatic episodic attacks associated with AFib-RVR.
The same records list Joseph Oliveto as President and Chief Executive Officer, Amit Hasija as Chief Financial Officer and EVP of Corporate Development, David B. Bharucha as Chief Medical Officer and Lorenz Muller as Chief Commercial Officer. The company was founded in 2005 and is headquartered in Montreal.
CARDAMYST Launch and Trial Enrollment
Milestone launched CARDAMYST commercially at U.S. retail pharmacies in January 2026, with national availability by late January and a national sales force deployment in mid-February 2026, the same records show. The launch was supported by a patient assistance program with a $25 projected copay cap.
In October 2026, Milestone announced the first European patient enrolled in ReVeRA-301, its Phase 3 trial of etripamil nasal spray for AFib-RVR, Stock Titan reported. The Dutch Cardiovascular Investigator Network site enrolled the patient, and enrollment targets about 150 patients.
Milestone's November 13 Results Call
Milestone will report its third-quarter 2026 financial results and a business update before market open on November 13, 2026, Stock Titan reported. The company will hold a conference call and webcast at 8:30 am ET.